<DOC>
	<DOC>NCT01574365</DOC>
	<brief_summary>A Phase 2 study of RTA 402 in Chronic kidney disease (CKD) patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>To evaluate the efficacy and safety of RTA 402 in patients with type 2 diabetes mellitus. To evaluate the safety and tolerability of RTA 402.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>CKD patients with type 2 diabetes mellitus Patients whose eGFR levels are eligible for this study Patients being treated with stable dose of ACE inhibitors and/or ARB etc. Patients with Type 1 diabetes Patients with known nondiabetic renal disease Patients with a history of renal transplantation Patients with mean SBP &gt; 160 mmHg or mean DBP &gt; 90 mmHg Patients with HbA1C &gt; 10% Patients with cardiovascular disease specified in the study protocol etc.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CKD patients with type 2 diabetes</keyword>
</DOC>